Anti-VEGF therapy improves outcomes in retinal diseases by targeting neovascularization and macular edema, crucial in conditions like AMD and diabetic retinopathy. Optical coherence tomography is ...

Please provide your email address to receive an email when new articles are posted on . Patients with inherited retinal diseases may present with seemingly routine conditions. Look for comorbid ...

Panelists discuss how emerging therapies—including TKIs, sustained-release implants, and gene therapy—may reduce treatment ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the ...

Find out how scientists are maximizing retinal organoid effectiveness to sustain critical retinal ganglion cells.

Patients with retinal diseases who were treated with anti-VEGF therapies through manufacturer patient assistance programs ...

Gene therapy emerges as a transformative force in ophthalmology, offering renewed hope for patients with retinal diseases. This innovative approach targets both inherited and acquired conditions, ...

The 2003 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) was held in May in Fort Lauderdale, Florida. The retinal sessions were dominated by reports of new treatments ...

Boehringer Ingelheim currently does not have any approved therapies for ophthalmic indications, but the company is looking to change that via a new $250m licensing deal with a US biotech. The deal is ...

Active TED patients showed higher thyrotropin receptor antibody levels and increased DCP vessel density.

Glaucoma has long been treated as a plumbing problem of the eye, managed mainly by lowering pressure rather than protecting ...